Navigating Drug Pricing Proposals and the Role of Value

Summary

Join Avalere’s panel of data analytics, market access, and policy experts for a discussion on the potential for federal drug pricing reform in Congress or via administrative action.

Access Recording

With Congress poised to consider a second reconciliation package, drug pricing reforms are likely to be on the agenda as a means to pay for permanent coverage expansion and other top priorities. In addition to the expected legislative landscape and as the Biden Administration takes shape, the debate over drug pricing reforms, especially “government negotiation,” is likely to reignite through CMMI and other regulatory vehicles.

Key Topics

Part D redesign
Government negotiation
International reference pricing
Linking payment to evidence and value
Part B drug reimbursement changes
Inflation rebates

Panelists

Moderator

Matt Kazan , Managing Director, Policy

Matt Kazan advises health plans, life sciences clients, and patient organizations as they navigate the policy landscape, focusing on Medicare Part D and Medicare Advantage, and implementation of the Inflation Reduction Act.

Speaker

Lance Grady , Executive Vice President, Life Sciences Strategy & Growth

Lance Grady is the head of Avalere’s Life Sciences Strategy & Growth.

Speaker

Milena Sullivan , Managing Director, Policy

Milena Sullivan advises life sciences clients on the impact of the evolving healthcare policy landscape on their commercial, access, and advocacy priorities.

Guest Speaker

Brian , Senior Director, Health Economics and Outcomes Research, Inovalon

Brian Leinwand provides strategic health economics support throughout a product’s life-cycle and helps clients build evidence packages that demonstrate and support the value of their products.